Our study demonstrated that Piezo1 is critically involved in arrhythmogenic remodeling after MI through Ca2+ regulation and revealed it as a new potential anti-arrhythmic target in the treatment of MI and heart failure. The gene discussed is PIEZO1; the disease is myocardial infarction.